Pathogens in Sepsis: Fungi, Parasites

Sepsis and Non-Infectious Systemic Inflammation: From Biology to Critical Care

Volumn , Issue , 2009, Pages 145-173

  Méchaï, Frédéric ^a   Bruneel, Fabrice ^b   Lanternier, Fanny ^a   Legriel, Stephane ^b   Bédos, Jean Pierre ^b   Lortholary, Olivier ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

Bloodstream infection (BSI); Candida species; Candidemia; Fungal sepsis; Innate immunity; Parasite induced sepsis; Parasitized red blood cells (pRBC); Severe falciparum malaria

Indexed keywords

EID: 84889434038     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527626151.ch7     Document Type: Chapter

References (105)

1. Martin, G.S., Mannino, D.M., Eaton, S. and Moss, M. (2003). The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med., 348, 1546-1554.
2. Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel, R.P. and Edmond, M.B. (2004). Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a retrospective nationwide surveillance study. CID, 39, 309-317.
3. Edwards, J.E., Bodey, G.P., Bowden, R.A., Büchner, T., de Pauw, B.E., Filler, S.G. and Ghannoum, M.A. (1997). International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. CID, 25, 43-59.
4. Ascioglu, S., Rex, J.H., de Pauw, B., Bennett, J.E., Crokaert, F., Denning, D.W., et al. (2002). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus. CID, 34, 7-14.
5. Blumberg, H.M., Jarvis, W.R., Soucie, J.M., Edwards, J.E., Patterson, J.E., Pfaller, A., et al. (2001). Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS Prospective Multicenter Study. CID, 33, 177-186.
6. Karabinis, A., Hill, C., Leclercq, B., Tancrede, C., Baume, D. and Andremont, A. (1988). Risk factors for candidemia in cancer patients: a case study. J. Clin. Microbiol., 26(3), 3-429.
7. Bross, J., Talbot, G.H., Maislin, G., Hurwitz, S. and Strom, B.L. (1989). Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am. J. Med., 87(6), 6-614.
8. Wey, S.B., Mori,M., Pfaller,M.A., Woolson, R.F. and Wenzel, R.P. (1989). Risk factors for hospital-acquired candidemia. A matched case-control study. Arch. Intern. Med., 149, 2349-2353.
9. McKinnon, P.S., Goff, D.A., Kern, J.W., Devlin, J.W., Barletta, J.F., Sierawski, S.J., et al. (2001). Temporal assessment of candida risk factors in the surgical intensive care unit. Arch. Surg., 136, 1401-1408.
10. Vincent, J.L., Anaissie, E., Bruining, H., Demajo, W., El-Ebiary, M., Haber, J., et al. (1998). Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med., 24, 206-216.
11. Wenzel, R.P. and Gennings, C. (2005). Bloodstream infections due to candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. CID, 41, S389-93.
12. Marchetti, O., Bille, J., Fluckiger, U., Eggimann, P., Ruef, C., Garbino, J., Calandra, T., Glauser, M.P., Täuber, M.G. and Pittet, D. (2004). Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. CID, 38, 311-320.
13. Pappas, P.G., Rex, J.H., Lee, J., Hamill, R.H., Larsen, R.A., Powderly, W., Kauffman, C.A., Hyslop, N., Mangino, J.E., Chapman, S., Horowitz, H.W., Edwards, J.E. and Dismukes, W.E. (2003). for the NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. CID, 37, 634-643.
14. Pfaller,M.A., Diekema, D.J., Jones, R.N., Sader, H.S., Fluit, A.C., Hollis, R.J., Messer, S.A. and the SENTRY participant group. (2001). International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J. Clin. Microbiol., 39, 3254-3259.
15. Richet, H., Roux, P., Des Champs, C., Esnault, Y., Andremont, A. and the French Candidemia Study Group. (2002). Candidemia in French hospitals:incidence rates and characteristics. Clin. Microbiol. Infect., 8, 405-412.
16. Trick, W.E., Fridkin, S.K., Edwards, J.R., Hajjeh, R.A. and Gaynes, R.P. (2002). The National Nosocomial Infections Surveillance System Hospitals. Secular trends of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. CID, 35, 627-630.
17. Hajjeh, R.A., Sofair, A.N., Harrison, L.H., Lyon, G.M., Arthington-Skaggs, B.A., Mirza, S.A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M.A., Benjamin, L.E., Sanza, L.T., Huie, S., Yeo, S.F., Brandt, M.E. and Warnock, D.W. (2004). Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol., 42, 1519-1527.
18. Tortorano, A.M., Kibbler, C., Peman, J., Bernhardt, H., Klingspor, L. and Grillot, R. (2006). Candidemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents, 27, 359-366.
19. Arendrup, M.C., Fuursted, K., Gahrn-Hansen, B., Jensen, I.M., Knudsen, J.D., Lundgren, B., et al. (2005). Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J. Clin. Microbiol., 43, 4434-4440.
20. Almirante, B., Rodriguez, D., Park, B.J., Cuenca-Estrella, M., Planes, A.M., Almela, M., et al. (2005). Epidemiology and predictors of mortality in cases of candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol., 43, 1829-1835.
21. Vincent, J.L., Sakr, Y., Sprung, C.L., Ranieri, V.M., Reinhart, K., et al. (2006). Sepsis in European intensive care units: results of the SOAP study. Crit. Care Med., 34, 344-353.
22. Romani, L. (2004). Immunity to fungal infections. Nat. Rev. Immunol., 4(1), 1-1.
23. Netea, M.G., Van Der Graaf, C.A., Vonk, A.G., Verschueren, I., Van Der Meer, J.W. and Kullberg, B.J. (2002). The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J. Infect. Dis., 185(10), 10-1483.
24. Cassone, A., Palma, C., Djeu, J.Y., Aiuti, F. and Quinti, I. (1993). Anticandidal activity and interleukin 1 beta and interleukin-6 production by polymorphonuclear leukocytes are preserved in subjects with AIDS. J. Clin. Microbiol., 31(5), 5-1354.
25. Castro, M., Bjoraker, J.A., Rohrbach, M.S. and Limper, A.H. (1996). Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytes. Inflammation, 20(1), 1-107.
26. Kobrynski, L.J., Tanimune, L., Kilpatrick, L., Campbell, D.E. and Douglas, S.D. (1996). Production of T-helper cell subsets and cytokines by lymphocytes from patients with chronic mucocutaneous candidiasis. Clin. Diagn. Lab. Immunol., 3(6), 6-740.
27. Xiong, J., Kang, K., Liu, L., Yoshida, Y., Cooper, K.D. and Ghannoum, M.A. (2000). Candida albicans and Candida krusei differentially induce human blood mononuclear cell interleukin-12 and gamma interferon production. Infect. Immun., 68(5), 5-2464.
28. Netea, M.G., Stuyt, R.J., Kim, S.H., Van der Meer, J.W., Kullberg, B.J. and Dinarello, C.A. (2002). The role of endogenous interleukin (IL)-18, IL-12, IL-1beta, and tumor necrosis factor-alpha in the production of interferon-gamma induced by Candida albicans in human whole-blood cultures. J. Infect. Dis., 185(7), 7-963.
29. Levitz, S.M. and North, E.A. (1996). Gamma interferon gene expression and release in human lymphocytes directly activated by Cryptococcus neoformans and Candida albicans. Infect. Immun., May 64(5), 1595-1599.
30. Jiang, Y., Russell, T.R., Graves, D.T., Cheng, H., Nong, S.H. and Levitz, S.M. (1996). Monocyte chemoattractant protein 1 and interleukin-8 production in mononuclear cells stimulated by oral microorganisms. Infect. Immun., 64(11), 11-4450.
31. Jeremias, J., Kalo-Klein, A. and Witkin, S.S. (1991). Individual differences in tumour necrosis factor and interleukin-1 production induced by viable and heat-killed Candida albicans. J. Med. Vet. Mycol., 29(3), 3-157.
32. Bellocchio, S., Montagnoli, C., Bozza, S., et al. (2004). The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J. Immunol., 172(5), 5-3059.
33. Marr, K.A., Balajee, S.A., Hawn, T.R., et al. (2003). Differential role of MyD88 in macrophage mediated responses to opportunistic fungal pathogens. Infect. Immun., 71(9), 9-5280.
34. Minami, A., Fujimoto, K., Ozaki, Y. and Nakamura, S. (1988). Augmentation of host resistance to microbial infections by recombinant human interleukin-1 alpha. Infect. Immun., 56(12), 12-3116.
35. Van Enckevort, F.H., Netea, M.G., Hermus, A.R., et al. (1999). Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice. Med. Mycol., Dec 37(6), 419-426.
36. Van der Graaf, C.A., Netea, M.G., Morre, S.A., et al. (2006). Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur. Cytokine Netw., 17(1), 1-29.
37. Meunier, F. (1989). Candidiasis. Eur. J. Clin. Microbiol. Infect. Dis., 8, 438-447.
38. Year, H., Sendid, B., Francois, N., Camus, D. and Poulain, D. (2001). Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis. Eur. J. Microbiol. Infect. Dis., 20, 864-870.
39. Weiner, M.H. and Coats-Stephen,M. (1979). Immunodiagnosis of systemic candidiasis: mannan antigenemia detected by radioimmunoassay in experimental and human infections. J. Infect. Dis., 140, 989-993.
40. Ostrosky-Zeichner, L., Rex, J.H., Bennett, J., et al. (2002). Deeply invasive candidiasis. Infect. Dis. Clin. North Am., 16, 821-835.
41. Stevens, D.A. (2002). Diagnosis of fungal infections: current status. JAC, 49, 11-19.
42. Meyer, M.H., Letscher-Bru, V., Jaulhac, B., Waller, J. and Candolfi, Ermanno. (2004). Comparison of mycosis IC/F and plus aerobic/F media for diagnosis of fungemia by the Bactec 9240 system. J. Clin. Microbiol., 42, 773-777.
43. Bougnoux, M.E., Hill, C., Moissenet, D., Feuilhade de Chauvin, M., Bonnay, M., Vicens-Sprauel, I., et al. (1990). Comparison of antibody, antigen, and metabolite assays for hospitalized patients with disseminated or peripheral candidiasis. J. Clin. Microbiol., 28, 905-909.
44. Sendid, B., Tabouret, M., Poirot, J.L., Mathieu, D., Fruit, J. and Poulain, D. (1999). Nex enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J. Clin. Microbiol., 37, 1510-1517.
45. Yeo, S.F. and Wong, B. (2002). Current status of nonculture methods for diagnosis of invasive fungal infections. Clin. Microbiol. Rev., 15, 465-484.
46. Morace, G., Pagano, L., Sanguinetti, M., Posteraro, B., Mele, L. and Equitani, F. (1999). PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with haematological malignancies. J. Clin. Microbiol., 37, 1871-1875.
47. Nolla-Salas, J., Sitges-Serra, A., Leon-Gil, C., Martinez-Gonzalez, J., Leon-Regidor, M.A., Ibanez-Lucia, P., et al. (1997). Candidemia in non-neutropenic critically ill patients:analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med., 23, 23-30.
48. Morrell, M., Fraser, V.J. and Kollef, M.H. (2005). Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antmicrob. Agents Chemother., 49, 3640-3645.
49. Vincent, J.L., Bihari, D.J., Suter, P.M., Bruining, H.A., White, J. and Nicolas-Chanoin, M.H. (1995). The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA, 274, 639-644.
50. Zaoutis, T.E., Argon, J., Chu, J., Berlin, J.A., Walsh, T.J. and Feudtner, C. (2005). The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. CID, 41, 1232-1239.
51. Rex, J.H., Bennett, J.E., Sugar, A.M., Pappas, P.G., Serody, J., Edwards, J.E. and Washburn, R.G. (1995). Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. CID, 21, 994-996.
52. Willinger, B. (2006). Laboratory Diagnosis and Therapy of Invasive Fungal Infections. Curr. Drug Targets, 7, 513-522.
53. Bates, D.W., Su, L., Yu, D.T., Chertow, G.M., Seger, D.L., Gomes, D.R.J., et al. (2001). Mortality and costs of acute renal failure associated with amphotericin B therapy. CID, 32, 686-693.
54. Kuse, E.R., Chetchotisakd, P., da Cuhna, C.A., Ruhnke, M., Barrios, C., Raghunadharao, D., et al. (2007). Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase 3 randomised double-blind trial. Lancet., 369, 1519-1527.
55. Pappas, P.G., Rex, J.H., Sobel, J.D., Filler, S.G., Dismukes, W.E., Walsh, T.J. and Edwards, J.E. (2004). Guidelines for treatment of candidiasis. CID, 38, 161-189.
56. Charlier, C., Hart, E., Lefort, A., Ribaud, P.,Dromer, F., Denning, D.W., et al. (2006) Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? JAC, 57, 384-410.
57. Pfaller, M.A., Diekema, D.J., Gibbs, D.L., Newell, V.A., Meis, J.F., Gould, I.M., et al. (2007). Results of the ARTEMIS DISK global antifungal surveillance study, 1997-2005: an 8.5 year analysis of susceptibilities of candida and other yeast species to fluconazole and voriconazole by CLSI standardized disk diffusion testing. J. Clin. Microbiol., 18 [Epub ahead of print].
58. Rex, J.H., Bennett, J.E., Sugar, A.M., Pappas, P.G., van der Horst, C.M., Edwards, J.E., et al. (1994). A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. NEJM, 331, 1325-1330.
59. Phillips, P., Shafran, S., Garber, G., Rotstein, C., Smaill, F., Fong, I., et al. (1997). Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian candidemia study group. Eur. J. Clin. Microbiol. Infect. Dis., 16, 337-345.
60. Johnson, L.B. and Kauffman, C.A. (2003). Voriconazole: a new Triazole antifungal Agent. CID, 36, 630-637.
61. Kullberg, J., Sobel, J.D., Ruhnke, M., Pappas, P.G., Viscoli, C., Rex, J.H., et al. (2005). Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet., 366, 1435-1442.
62. Lortholary, O., Dannaoui, E., Raoux, D., Hoinard, D., Datry, A., Paugam, A., et al. (2007). In vitro susceptibility to posaconazole of 1903 yeast isolates recovered in France (2003-2006) and tested by the EUCAST method. Antimicrob. Agents Chemother., 18 [Epub ahead of print].
63. Marr, K.A., White, T.C., van Burik, J.A.H. and Bowden, R.A. (1997). Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. CID, 25, 908-910.
64. Ostrosky-Zeichner, L. and Pappas, P.G. (2006). Invasive candidiasis in the intensive care unit. Crit. Care. Med., 34, 857-863.
65. Reboli, A.C., Rotstein, C., Pappas, P.G., Chapman, S.W., Kett, D.H., Kumar, D., et al. (2007). Anidulafungin versus Fluconazole for invasive candidiasis. N. Engl. J. Med., 356, 2472-2482.
66. Nucci, M. and Anaissie, E. (2002). Should vascular catheters be removed from all patients with candidemia? An evidence-based review. CID, 34, 591-599.
67. Sachs, J. and Malaney, P. (2002). The economic and social burden of malaria. Nature, 415, 680-685.
68. Jelinek, T., Schulte, C., Behrens, R., et al. (2002). Imported falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin. Infect. Dis., 34, 572-576.
69. Legros, F., Arnaud, A., El Mimouni, B. and Danis, M. (2006). Paludisme d'importation en France métropolitaine: données épidémiologiques 2001-2004. Bull. Epidémiol. Hebdomadaire, 32, 235-236.
70. Holtz, T.H., Kachur, S.P., MacArthur, J.R., Roberts, J.M., Barber, A.M., Steketee, R.W. and Parise, M.E. (2001). Malaria surveillance-United States, 1998. Mor. Mortal. Wkly. Rep. CDC. Surveill. Summ., 50, 1-20.
71. World Health Organization. (1990). Severe and complicated malaria. Trans. R. Soc. Trop. Med. Hyg., 84, 1-65.
72. World Health Organization. (2000). Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg., 94, 1-90.
73. Correction. World Health Organization. (2000). Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg., 94, 3.
74. Bruneel, F., Hocqueloux, L., Chevret, S., Regnier, P. and Vachon, F. (1999). Paludisme d'importationà P. falciparum. Quelle est la pertinence des critères de gravité de l'Organisation Mondiale de la Santé? Méd. Malad. Infect., 29(Suppl. 3), 345-355.
75. Bruneel, F., Hocqueloux, L., Alberti, C., et al. (2003). The clinical spectrum of severe imported falciparum malaria in the intensive care unit. Am. J. Respir. Crit. Care. Med., 167, 684-689.
76. White, N.J. and Ho, M. (1992). The pathophysiology of malaria. Adv. Parasitol., 31, 83-173.
77. Van der Heyde, H.C., Nolan, J., Combes, V., Gramaglia, I. and Grau, G.E. (2006). A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. Trends Parasitol., 22, 503-508.
78. Dondorp, A.M., Kager, P.A., Vreeken, J. and White, N.J. (2000). Abnormal blood flow and red blood cell deformability in severe malaria. Parasitol. Today, 16, 228-232.
79. Idro, R., Jenkins, N.E. and Newton, C.R. (2005). Pathogenesis, clinical faetures and neurological outcome of cerebral malaria. Lancet. Neurol., 4, 827-840.
80. Dondorp, A.M., Desakorn, V., Pongtavornpinyo, W., et al. (2005). Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PloS. Med., 2, e204.
81. Pain, A., Ferguson, D.J., Kai, O., et al. (2001). Platelet-mediated clumping of Plasmodium falciparum-infected erythrocytes is a common adhesive phenotype and is associated with severe malaria. Proc. Natl. Acad. Sci. USA., 98, 1805-1810.
82. Combes, V., Taylor, T.E., Juhan-Vague, I., et al. (2004). Circulating endothelial microparticles in Malawian children with severe falciparum malaria complicated with coma. JAMA, 291, 2542-2544.
83. Kwiatkowski, D.P. and Luoni, G. (2005). Host genetic factors in resistance and susceptibility to malaria, in Molecular Approaches to Malaria. ASM Press, USA.
84. Daily, J.P., Le Roch, K.G., Sarr, O., et al. (2004). In vivo transcriptional profiling of Plasmodium falciparum. Malaria J., 3, 30.
85. Daily, J.P., Le Roch, K.G., Sarr, O., et al. (2005). In vivo transcriptome of Plasmodium falciparum reveals overexpression of transcripts that encode surface proteins. J. Infect. Dis., 191, 1196-1203.
86. Jafari, S., Le Bras, J., Bouchaud, O. and Durand, R. (2004). Plasmodium falciparum clonal population dynamics during malaria treatment. J. Infect. Dis., 189, 195-203.
87. Olumese, P.E., Amodu, O.K., Björkman, A., et al. (2002). Chloroquine resistance of Plasmodium falciparum is associated with severity of disease in Nigerian children. Trans. R. Soc. Trop. Med. Hyg., 96, 418-420.
88. World Health Organization. Guidelines for the Treatment of Malaria, WHO, Geneva, 2006.
89. Looareesuwan, S., Wilairatana, P., Krishna, S., et al. (1995). Magnetic resonance imaging of the brain in cerebral malaria. Clin. Infect. Dis., 21, 300-309.
90. Bruneel, F., Gachot, B., Timsit, J.F., et al. (1997). Shock complicating severe falciparum malaria in European adults. Int. Care. Med., 23, 698-701.
91. Hocqueloux, L., Bruneel, F., Lagorce Pages, C. and Vachon, F. (2000). Fatal invasive aspergillosis complicating severe Plasmodium falciparum malaria. Clin. Infect. Dis., 30, 940-942.
92. Maitland, K. and Newton, C.R. (2005) Acidosis of severe falciparum malaria: heading for a shock? Trends Parasitol., 21, 11-16.
93. Gachot, B., Wolff, M., Nissack, G., et al. (1995). Acute lung injury complicating imported Plasmodium falciparum malaria. Chest, 108, 746-749.
94. Hien, T.T., Day, N.P.J., Phu, N.H., et al. (1996). A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N. Engl. J. Med., 335, 76-83.
95. Dondorp, A.M., Nosten, F., Stepniewska, K., et al. (2005). Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet., 366, 717-725.
96. Bruneel, F., Gachot, B., Wolff, M., et al. (2001). Resurgence of blackwater fever in long-term European expatriates in Africa. Report of 21 cases and review. Clin. Infect. Dis., 32, 1133-1140.
97. White, N.J. (2003). The management of severe falciparum malaria. Am. J. Resp. Crit. Care. Med., 167, 673-674.
98. Lesi, A. and Meremikwu, M. (2004). High first dose quinine regimen for treating severe malaria. Cochrane. Database Syst. Rev.,. (3) , CD003341.
99. Artemether-quinine Meta-analysis Study Group. (2001). A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg., 95, 637-650.
100. Dellinger, R.P., Carlet, J.M., Masur, H., et al. (2004). Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med., 32, 858-873.
101. Nau, A., Peytel, E. and Petrognani, R. (2006). Is there a place for activated protein C in the treatment of severe imported falciparum malaria in adult? Ann. Fr. Anesth. Reanim., 25, 1085-1086.
102. Bruneel, F., Hocqueloux, L., Legriel, S., et al. (2007). Activated protein C during severe imported falciparum malaria: look at benefit/risk ratio. Ann. Fr. Anesth. Reanim., 26, 263-264.
103. Pasvol, G. (2005). Management of severe malaria: interventions and controversies. Infect. Dis. Clin. N. Am., 19, 211-240.
104. Riddle, M.S., Jackson, J.L., Sanders, J.W. and Blazes, D.L. (2002). Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis. Clin. Infect. Dis., 34, 1192-1198.
105. Kaiser, K., Texier, A., Ferrandiz, J., et al. (2006). Recombinant human erythropoietin prevents the death of mice during cerebral malaria. J. Infect. Dis., 193, 987-995.